In the field of NASH (Non-Alcoholic SteatoHepatitis) particularly, many pharmacological targets are known to be involved both in metabolism and in the clock, calling for a need to consider chronopharmacology in the design of clinical trials, which may limit the variability of trial outcomes that have been observed so far [119]. The gene discussed is CLOCK; the disease is metabolic dysfunction-associated steatohepatitis.